How GLP-1 may reduce CPAP dependence CPAP therapy remains the gold standard for OSA treatment, yet many find it uncomfortable or inconvenient 36
FACS trafficking MIN6B1-SNAP-GLP-1R or CHO-SNAP-GLP-1R cells were pre-incubated in HEPES-bicarbonate buffer plus 3 mM glucose and 1% BSA before labeling at 37 C with 1 M cleavable BG-SS-488 SNAP-Surface probe (a gift from New England Biolabs) and stimulation with 100 nM agonist in HEPES-bicarbonate buffer plus 11 mM glucose and 1% BSA, and trafficking assays performed as follows 27 : Briefly, for receptor internalization, cells were placed at 4 C to arrest endocytosis following incubation at 37 C for the indicated times, or directly put at 4 C for 0 min time-point, and treated with ice-cold alkaline TNE buffer 100 mM MesNa to strip surface-exposed label (plus MesNa) or to measure total labeled receptor (minus MesNa)
GLP-1s are a large topic, so we will explore their risks, benefits, MCAS/histamine applications, and root-cause considerations more deeply in a separate article
The drug, to be marketed in the U.S
Nearly two decades ago, the first GLP-1 RA agonist was approved for the treatment of type 2 diabetes 1